Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.
Metrics to compare | CLBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLBIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −21.1x | −4.6x | −0.6x | |
PEG Ratio | 0.02 | −0.12 | 0.00 | |
Price/Book | 2.4x | 3.4x | 2.6x | |
Price / LTM Sales | 8.6x | 18.5x | 3.1x | |
Upside (Analyst Target) | 142.6% | 54.6% | 55.4% | |
Fair Value Upside | Unlock | 1.5% | 10.2% | Unlock |